A Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (>=10 to <18 Years) With Type 2 Diabetes Mellitus

NCT03170518 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

171

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: Canagliflozin 100 mg
DRUG: Canagliflozin 300 mg
DRUG: Placebo

Sponsor

Janssen Research & Development, LLC